CGC, GENE and HOLO among mid-day movers
Seeking Alpha News (Thu, 18-Apr 12:42 PM ET)
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Aptorum Group Limited - Class A trades on the NASDAQ stock market under the symbol APM.
As of April 22, 2024, APM stock price declined to $5.66 with 18,732 million shares trading.
APM has a beta of -0.27, meaning it tends to be less sensitive to market movements. APM has a correlation of 0.00 to the broad based SPY ETF.
APM has a market cap of $30.97 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, APM stock traded as high as $35.40 and as low as $1.35.
The top ETF exchange traded funds that APM belongs to (by Net Assets): ONEQ.
APM has outperformed the market in the last year with a return of +97.9%, while the SPY ETF gained +22.3%. In the last 3 month period, APM beat the market returning +232.9%, while SPY returned +3.9%. However, in the most recent 2 weeks APM has underperformed the stock market by returning -29.3%, while SPY returned -3.6%.
APM support price is $5.15 and resistance is $6.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APM stock will trade within this expected range on the day.